Our latest white paper explores how pharmaceutical companies can manage and benefit from Facebook in light of Facebook’s new policy to require open comments.
Yesterday, Pharmalot reported that some drugmakers may abandon Facebook if they can’t cope with the changes. They interviewed several drugmakers about their plans, including Sanofi and AstraZeneca, who acknowledge that they may walk away from Facebook if they cannot overcome concerns posed by the new policy.
We hope our white paper will offer some options to pharmaceutical companies like Sanofi and AstraZeneca. Facebook is a powerful platform and, as Sanofi said to Pharmalot, “patients are increasingly turning to Facebook for information and we feel it is important to be part of the dialogue.”
White Paper Summary:
A new Facebook policy will require all pharmaceutical companies to leave wall comments enabled on their Facebook pages. The rule not only leaves pharma companies open to public criticism, it also complicates federal rules requiring companies to report all stated drug side effects to the relevant authorities, a rule set in 1993, long before the advent of social media. However, Facebook is an opportunity for pharma – not an obstacle. The key is to embrace, rather than fight, its open features.
This white paper looks at Johnson & Johnson’s ongoing challenges with negative comments on their Facebook page, and how companies like Boehringer Ingelheim and Sanofi-Aventis have sustained positive conversation on their own pages. We also explore how other pharmaceutical companies, such as Abbott, Bayer, Eli Lilly, Merck, Pfizer and others can manage open comments, protect their reputations and benefit from the 600 million people currently using Facebook.
Download the white paper:
We welcome you to share your thoughts and feedback in the comments below.